3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Ovarian Neoplasms
4
Endometrial Neoplasms
3
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
6
Nivolumab
3
Cisplatin
3
Carboplatin
3
Paclitaxel
2
Fluorouracil
2
tucatinib
1
pertuzumab
1
milademetan
1
lenvatinib
1
cemiplimab
1
Trastuzumab
1
Tomography, X-Ray Computed
1
Ritonavir
1
Radiation
1
Prednisone
1
Prednisolone
1
Positron-Emission Tomography
1
Pemetrexed
1
Oxaliplatin
1
Magnetic Resonance Imaging
1
Leucovorin
1
Itraconazole
1
Gemcitabine
1
Fulvestrant
1
Cetuximab
1
Capecitabine
1
Brachytherapy
1
Bevacizumab
1
AZD9833
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Biliary Tract Neoplasms
×
AZD5305
×
Gynecologic
×
Clear all
NCT04644068
2026-02-19
PETRA
AstraZeneca
Phase 1/2
Active not recruiting
702 enrolled